Q-omics provides the consensus-scored RFPL3S profile across patient tissues and cancer cell-line models. RFPL3S expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RFPL3S is differentially expressed in 5, with the highest sampling consensus in CHOL. Additionally, RFPL3S RNA expression shows 17,068 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, CHOL, and UVM as cancer lineages where RFPL3S shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RFPL3S — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RFPL3S survival associations across molecular data types. RFPL3S RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RFPL3S RNA expression–survival associations across cancer types. High RFPL3S expression shows unfavorable associations in KIRC, ACC and COAD, but favorable associations in BLCA, UCS and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RFPL3S RNA expression.
This table summarizes RFPL3S tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for RFPL3S. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RFPL3S shows lower tumor expression in THCA and higher tumor expression in CHOL, LUSC, KIRC and LIHC. The CHOL box plot shows higher RFPL3S RNA expression in tumor versus normal tissue (log2 FC = +1.091, t-test p < 0.001).
This table shows molecular features associated with RFPL3S in patient tissues and cancer cell lines. In patient samples, RFPL3S shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RFPL3S RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
